Martin LA - Search Results

1

PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance.

Montaudon E, Nikitorowicz-Buniak J, Sourd L, Morisset L, El Botty R, Huguet L, Dahmani A, Painsec P, Nemati F, Vacher S, Chemlali W, Masliah-Planchon J, Château-Joubert S, Rega C, Leal MF, Simigdala N, Pancholi S, Ribas R, Nicolas A, Meseure D, Vincent-Salomon A, Reyes C, Rapinat A, Gentien D, Larcher T, Bohec M, Baulande S, Bernard V, Decaudin D, Coussy F, Le Romancer M, Dutertre G, Tariq Z, Cottu P, Driouch K, Bièche I, Martin LA, Marangoni E. Montaudon E, et al. Among authors: martin la. Nat Commun. 2020 Aug 13;11(1):4053. doi: 10.1038/s41467-020-17697-1. Nat Commun. 2020. PMID: 32792481 Free PMC article.

2

Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.

Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, Dowsett M. Johnston SR, et al. Among authors: martin la. Clin Cancer Res. 2003 Jan;9(1 Pt 2):524S-32S. Clin Cancer Res. 2003. PMID: 12538510 Review.

3

The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.

Martin LA, Head JE, Pancholi S, Salter J, Quinn E, Detre S, Kaye S, Howes A, Dowsett M, Johnston SR. Martin LA, et al. Mol Cancer Ther. 2007 Sep;6(9):2458-67. doi: 10.1158/1535-7163.MCT-06-0452. Mol Cancer Ther. 2007. PMID: 17876043

4

The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.

Banerjee S, Pancholi S, A'hern R, Ghazoui Z, Smith IE, Dowsett M, Martin LA. Banerjee S, et al. Among authors: martin la. Clin Cancer Res. 2008 May 1;14(9):2656-63. doi: 10.1158/1078-0432.CCR-07-1352. Clin Cancer Res. 2008. PMID: 18451229 Clinical Trial.

5

ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.

Pancholi S, Lykkesfeldt AE, Hilmi C, Banerjee S, Leary A, Drury S, Johnston S, Dowsett M, Martin LA. Pancholi S, et al. Among authors: martin la. Endocr Relat Cancer. 2008 Dec;15(4):985-1002. doi: 10.1677/ERC-07-0240. Epub 2008 Sep 29. Endocr Relat Cancer. 2008. PMID: 18824559

6

Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.

Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, Dowsett M, Johnston SR. Leary AF, et al. Among authors: martin la. Clin Cancer Res. 2010 Mar 1;16(5):1486-97. doi: 10.1158/1078-0432.CCR-09-1764. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179226

7

ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1.

Dunbier AK, Anderson H, Ghazoui Z, Lopez-Knowles E, Pancholi S, Ribas R, Drury S, Sidhu K, Leary A, Martin LA, Dowsett M. Dunbier AK, et al. Among authors: martin la. PLoS Genet. 2011 Apr;7(4):e1001382. doi: 10.1371/journal.pgen.1001382. Epub 2011 Apr 28. PLoS Genet. 2011. PMID: 21552322 Free PMC article.

8

Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.

Weigel MT, Ghazoui Z, Dunbier A, Pancholi S, Dowsett M, Martin LA. Weigel MT, et al. Among authors: martin la. Breast Cancer Res. 2012 May 18;14(3):R78. doi: 10.1186/bcr3191. Breast Cancer Res. 2012. PMID: 22608253 Free PMC article.

9

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.

Martin LA, Pancholi S, Farmer I, Guest S, Ribas R, Weigel MT, Thornhill AM, Ghazoui Z, A'Hern R, Evans DB, Lane HA, Johnston SR, Dowsett M. Martin LA, et al. Breast Cancer Res. 2012 Oct 17;14(5):R132. doi: 10.1186/bcr3330. Breast Cancer Res. 2012. PMID: 23075476 Free PMC article.

10

GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.

Morandi A, Martin LA, Gao Q, Pancholi S, Mackay A, Robertson D, Zvelebil M, Dowsett M, Plaza-Menacho I, Isacke CM. Morandi A, et al. Among authors: martin la. Cancer Res. 2013 Jun 15;73(12):3783-95. doi: 10.1158/0008-5472.CAN-12-4265. Epub 2013 May 6. Cancer Res. 2013. PMID: 23650283 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

308 results

Search Page

Filters